AIRNA is pioneering the discovery and development of RNA editing therapeutics to transform the lives of patients with rare and common diseases. RNA editing is poised to lead the next generation of RNA therapeutics by targeting diseases not accessible through other approaches with a medicine that can be conveniently re-dosed and manufactured. Our RESTORE+ platform is based on groundbreaking research by academic co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University), who were the first to elucidate a therapeutic approach for precise editing of RNA. AIRNA is advancing its first therapeutic program, a best-in-class product candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD), as well as a pipeline of therapeutic candidates to address multiple diseases with high unmet need. AIRNA has headquarters in Cambridge, MA, with research operations in Tübingen, Germany.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/31/24	$90,000,000	Series A	Alexandria Venture Investments ARCH Venture Partners Forbion Capital Partners ND Capital Ono Venture Investment	undisclosed